Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

DNA Microarrays02:34

DNA Microarrays

Microarrays are high-throughput and relatively inexpensive assays that can be automated to analyze large quantities of data at a time. They are used in genome-wide studies to compare gene or protein expression under two varied conditions, such as healthy and diseased states. Microarrays consist of glass or silica slides on which probe molecules are covalently attached through surface functionalization. Most commonly, the slides are prepared through the chemisorption of silanes to silica...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Increasing Trends of Minimal Residual Disease Measurement in Trials Focusing on Multiple Myeloma Treatment: A Systematic Analysis of Clinical Research Design From 2014 to 2025.

European journal of haematology·2026
Same author

Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 Trial.

European journal of haematology·2025
Same author

Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Correction: Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma.

Journal of hematology & oncology·2025
Same author

Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma.

Journal of hematology & oncology·2024
Same author

Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation.

JCO precision oncology·2024

Related Experiment Video

Updated: Jul 16, 2026

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker
07:47

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Published on: September 15, 2023

Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis.

Maud Condomines1, Dirk Hose, Pierre Raynaud

  • 1Institute of Research in Biotherapy, Centre Hospitalier Universitaire Montpellier, Montpellier, France.

Journal of Immunology (Baltimore, Md. : 1950)
|February 22, 2007
PubMed
Summary

Cancer-testis (CT) antigens are promising targets for cancer vaccines. This study found that most multiple myeloma patients express multiple CT antigens, suggesting their potential for personalized vaccination strategies.

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Related Experiment Videos

Last Updated: Jul 16, 2026

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker
07:47

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Published on: September 15, 2023

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • Cancer-testis (CT) antigens are expressed in the testis and malignant tumors but rarely in normal tissues, making them attractive targets for cancer vaccination.
  • Multiple myeloma (MM) is a hematologic malignancy with potential for targeted therapies.

Purpose of the Study:

  • To evaluate the expression of CT genes in multiple myeloma (MM) on a pangenomic scale.
  • To determine the prognostic value of CT gene expression in MM.
  • To establish strategies for selecting CT antigens for clinical vaccination trials.

Main Methods:

  • Gene expression profiling of CT genes in purified MM cells from 64 newly diagnosed MM patients and 12 monoclonal gammopathy of unknown significance patients.
  • Analysis of normal plasma cells, B cells, and 20 MM cell lines.
  • Statistical analysis to correlate CT gene expression with event-free survival.

Main Results:

  • 35 out of 46 interrogated CT genes were expressed in MM cells (MMC) of at least one patient; 25 are on chromosome X.
  • Expression of six CT genes correlated with shorter event-free survival.
  • 98% of MM patients expressed at least one CT gene, 86% expressed at least two, and 70% expressed at least three.
  • A panel of 10 CT genes could identify at least three CT antigens in 67% of patients.

Conclusions:

  • CT gene expression is widespread in multiple myeloma, with a significant proportion of patients expressing multiple antigens.
  • CT gene expression patterns may hold prognostic value and can inform the selection of antigens for personalized cancer vaccines.
  • Gene expression profiling can guide the identification of suitable CT antigens for vaccination strategies in MM, potentially overcoming tumor escape mechanisms.